Robert Azelby
CIK 1656998 · President & CEO · last filed 2026-07-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.21M
Companies
12
Total Filings
48
Lifetime Open-Market Net
-$14.08M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AUTL | Director | — | $1.44 | — | $0 | 1 | 2026-07-01 |
| TNGX | Director | 5,740 | $25.98 | $149.1K | $0 | 1 | 2026-06-23 |
| ADCT | Director | 112,805 | $1.09 | $123.0K | -$20.2K | 5 | 2026-06-03 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Director | — | $52.95 | — | $0 | 3 | 2026-05-05 |
| CAH | Director | 4,085 | $228.81 | $934.7K | $0 | 3 | 2025-11-06 |
| CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Director | — | $40.39 | — | $0 | 2 | 2023-08-11 |
| Climb Bio, Inc. (ELYM) Delisted | President & CEO | — | $5.11 | — | $0 | 2 | 2022-11-02 |
| Clovis Oncology, Inc. (CLVS) Delisted | Director | — | $0.08 | — | $0 | 4 | 2021-06-11 |
| IMMUNOMEDICS INC (IMMU) Delisted | Director | 3,718 | — | — | $0 | 3 | 2020-10-23 |
| ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | President and CEO | — | — | — | $0 | 3 | 2019-04-25 |
| Juno Therapeutics, Inc. (JUNO) Delisted | EVP & Chief Commercial Officer | 0 | — | — | -$14.06M | 16 | 2018-03-07 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | Director | — | — | — | $0 | 2 | 2017-06-13 |
Recent Filings · Page 2 of 5
48 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-18 | ADCT | Sell (S) | −6,995 | -$20.2K | EDGAR |
| 2024-06-18 | ADCT | Notice (144) | −6,995 | -$20.2K | EDGAR |
| 2024-06-14 | ADCT | Grant (A) | +40,000 | $0 | EDGAR |
| 2024-03-18 | CAH | Grant (A) | +1,288 | $0 | EDGAR |
| 2023-08-11 | CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Disp (D) | — | $0 | EDGAR |
| 2023-04-12 | CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-11-02 | Climb Bio, Inc. (ELYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-01-31 | Climb Bio, Inc. (ELYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-11 | Clovis Oncology, Inc. (CLVS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-10-23 | IMMUNOMEDICS INC (IMMU) Delisted | Disp (D) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.